



CytoSorbents

Working to Save Lives Through Blood Purification

CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment Conference

MONMOUTH JUNCTION, NJ – September 7, 2016 - CytoSorbents Corporation (NASDAQ: [CTSO](#)), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that CEO Dr. Phillip Chan, MD, PhD, will present at the [Rodman & Renshaw 18th Annual Global Investment Conference](#) (sponsored by H.C. Wainwright & Co) taking place September 11-13, 2016 in New York City.

Currently, the company is scheduling one-on-one meetings with the management team and institutional investors for September 12th and 13th. To schedule a meeting, please contact Lea Garcia at lgarcia@cytosorbents.com.

Conference Presentation Details:

Where: New York Palace Hotel, 455 Madison Ave, New York, NY 10022

When: Monday, September 12th at 11:15 AM ET

Room: Holmes I (4th Floor)

Webcast: <http://wsw.com/webcast/rrshq26/ctso>

Conference Website: [Rodman and Renshaw 18th Annual Global Investment Conference](#)

About CytoSorbents Corporation

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 37 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents is currently conducting its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study evaluating the safety

of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In early 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 14,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of \$18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb and others. For more information, please visit the Company's websites: <http://www.cytosorbents.com> and <http://www.cytosorb.com> or follow us on [Facebook](#) and [Twitter](#).

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow us on [Facebook](#) and [Twitter](#)

Cytosorbents Contact:

Amy Vogel
Investor Relations
(732) 329-8885 ext. *825
avogel@cytosorbents.com

Public Relations Contact:

Amy Phillips
Pascale Communications
412-327-9499
amy@pascalecommunications.com